CALIFORNIA | LOCAL
May 17, 1996 |
Researcher Kavita Arora, an assistant professor in developmental and cell biology, was one of 15 individuals throughout the United States recently named as a Searle Scholar for 1996. Arora will receive $180,000 for her research over the next three years. She is studying the role of two genes in the embryonic growth of fruit flies.
CALIFORNIA | LOCAL
June 18, 2002 |
John A. Cella, 76, a chemist who guided development of the skin care lines Visible Difference and Millennium for Elizabeth Arden, died June 8 in San Diego of kidney failure. A native of Chicago, Cella earned his bachelor's degree at DePaul University there and his doctorate at the University of Notre Dame. He spent most of his life in the Midwest, until his 1986 retirement from Elizabeth Arden, when he moved to San Diego and became a consultant to various cosmetics companies.
CALIFORNIA | LOCAL
March 21, 2002 |
John E. Robson, the president and chairman of the Export-Import Bank of the United States, a government-held corporation that helps U.S. businesses compete abroad as they export goods and services, died of cancer Wednesday at his home in Washington, D.C. He was 71. Robson, a former chief executive at major corporations, had held top government positions intermittently since the late 1960s in agencies covering transportation and banking.
August 25, 1998 |
Monsanto Co. said its much-anticipated painkiller, one of a new class of drugs with multibillion-dollar sales potential for conditions such as arthritis, will get a faster-than-usual review by the Food and Drug Administration. The priority review designation generally means that the FDA will decide whether to approve the drug within six months instead of a year. Monsanto, which expects to complete a merger with American Home Products Corp.
November 13, 1985 |
A new report suggests that NutraSweet might trigger epilepsy in some susceptible people and recommends that doctors question seizure victims about their consumption of the popular artificial sweetener. In the current issue of the British journal Lancet, Dr. Richard J. Wurtman describes three cases in which persons had their first epileptic seizures after drinking large amounts of soft drinks that contained NutraSweet.
March 16, 1988 |
Monsanto Co. shares fell sharply again Tuesday as a major product-liability lawsuit continued to draw unwanted publicity for the chemicals conglomerate, although some analysts were saying that the selling had been overdone. The company's stock fell $3.25 to $80.125, after a $3.125 drop the day before, amid safety concerns over its G. D. Searle & Co. unit's Copper-7 intrauterine device. The drop in the stock was enough to prompt analysts at Merrill Lynch & Co.
March 26, 1985 |
G. D. Searle & Co., maker of the popular NutraSweet sugar substitute, said Monday that it had ended its search for a possible buyer of all or part of the company and would remain independent. The Skokie, Ill.-based pharmaceutical company announced last September that it was exploring a sale at the request of the Searle family, which wanted to diversify its 34% stake. Among the firms that expressed interest in Searle were Pfizer Inc., Monsanto and Angus Chemical Co.
February 22, 1990 |
The Food and Drug Administration today cleared the use in frozen desserts of Simplesse, a fat substitute made from milk and egg proteins, marking a major breakthrough in the diet food industry. Simplesse, developed by NutraSweet Co., a subsidiary of St. Louis-based Monsanto Co., is the first fat substitute to be approved in the American market. The introduction of NutraSweet, the artificial sweeetener used in soft drinks, by G. D. Searle & Co.